A Cambridgeshire-based manufacturer of infection prevention and contamination control products has reported a rise in profits from June 2013 to the same period this year.
Tristel’s revenues rose 28% to £13.5m this year compared to £10.6m in 2013. It also reported a boost in profits before tax to £1.8m from £0.48m the previous year.
Bosses say that the success is down to an 18–month restructuring plan, as well as new products and investment.
In addition, Tristel reversed the decline on sales of its legacy endoscopy products by substituting them with new ones.
Earnings per share also increased to 3.25p for the full year compared to 2014’s 3.16p, while cash and equivalents increased to £2.6m from £0.6m in the year before.
Christopher Samler, company chairman said: “Our market environment globally is moving increasingly in the direction of a more data driven approach to disinfection.”
Chief executive Paul Swinney added: “By focusing upon the group’s core competence of innovation and product development, and with a disciplined and targeted approach, I feel confident that Tristel will deliver continued growth into the future.”
Analysts from FinnCap commented that the suggested dividend of 1.6p was an improvement on the last year’s 0.4p.
On Monday, shares were down 0.94% to 73.8p.
